SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2757-2760. Prepublished online as a Blood First Edition Paper on June 19, 2007; DOI 10.1182/blood-2007-03-080820. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-03-080820v1 110/7/2757    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lilleri, D. Articles by Locatelli, F. Search for Related Content PubMed PubMed Citation Articles by Lilleri, D. Articles by Locatelli, F. Related Collections Transplantation Brief Reports Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief Report Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia Daniele Lilleri1, Giuseppe Gerna1, Milena Furione1, Maria Ester Bernardo2, Giovanna Giorgiani2, Stefania Telli2, Fausto Baldanti1, and Franco Locatelli2 1 Servizio di Virologia, and 2 Oncoematologia Pediatrica, Università di Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy We performed a randomized trial comparing the use of quantitative DNAemia versus positive antigenemia for starting preemptive antihuman cytomegalovirus (HCMV) therapy in hematopoietic stem-cell transplantation (HSCT) recipients. In the DNAemia arm, antiviral therapy was initiated on reaching a DNAemia cut-off of 10 000 DNA copies/mL of whole blood, whereas in the antigenemia arm, therapy was started in the presence of a positive antigenemia. The aim of the study was to compare the number of patients treated in the 2 arms. On the whole, 178 patients (89 in each arm), receiving unmanipulated HSCT from either a relative or an unrelated donor, completed the study. Although the incidence of HCMV infection was comparable in DNAemia and antigenemia arms (34% vs 42%, respectively, P = .259), the number of patients treated was significantly lower in the DNAemia arm (18% vs 31%, P = .026). No patient developed HCMV disease. The use of a DNAemia cut-off avoids unnecessary antiviral treatment. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Clarification of data used in three studies on MCA-induction of sarcoma in mice Mark J. Smyth Blood 2008 111: 4419. [Full Text] [PDF] Response: Human cytomegalovirus DNAemia and preemptive treatment of HCMV infection in children receiving hematopoietic stem-cell transplantation Giuseppe Gerna, Daniele Lilleri, and Franco Locatelli Blood 2008 111: 4420. [Full Text] [PDF] This article has been cited by other articles: G. Gerna, D. Lilleri, and F. Locatelli Response: Human cytomegalovirus DNAemia and preemptive treatment of HCMV infection in children receiving hematopoietic stem-cell transplantation Blood, April 15, 2008; 111(8): 4420 - 4420. [Full Text] [PDF] S. Cesaro, D. Abate, and C. Mengoli Human cytomegalovirus DNAemia and preemptive treatment of CMV infection in children after hematopoietic stem-cell transplantation: Is any question settled? Blood, April 15, 2008; 111(8): 4419 - 4419. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020